FCM
KALV

Flinton Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Flinton Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$15K Hold
1,292
– – ﹤0.01% 875
2019
Q2 		$29K Hold
1,292
– – ﹤0.01% 856
2019
Q1 		$37K Hold
1,292
– – ﹤0.01% 829
2018
Q4 		$26K Buy
+1,292
New +$26K ﹤0.01% 821

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flinton Capital Management's KALV Position: Q3 2019 in Review

Flinton Capital Management held its KalVista Pharmaceuticals (KALV) position steady in Q3 2019 at 1,292 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #875.

Flinton Capital Management first reported a position in KALV in Q4 2018 and has held it in 4 quarters since. The position peaked at $37K in Q1 2019. 76 funds tracked by Wall St. Rank hold KALV as of Q3 2019.

  • Flinton Capital Management held 1,292 shares of KalVista Pharmaceuticals worth $15K as of Q3 2019.
  • Flinton Capital Management left its KalVista Pharmaceuticals share count unchanged in Q3 2019.
  • KalVista Pharmaceuticals made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #875 holding.
  • Flinton Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2018 and has held it in 4 quarters since.
  • Flinton Capital Management's KalVista Pharmaceuticals position peaked at $37K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.